1. Summary of Demographics
  Output: Out14.1.1
  1.1. Summary of Subjects by Treatment
    Analysis: An01.05_SAF_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADSL.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis 
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis 
  1.2. Age
    1.2.1. Summary by Treatment
      Analysis: An03.01_Age_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADSL.AGE
        Method: Summary by group of a continuous variable
          Operations:
            > Mth02_ContVar_Summ_ByGrp_1_n: Count of non-missing values (n)
            > Mth02_ContVar_Summ_ByGrp_2_Mean: Mean (Mean)
            > Mth02_ContVar_Summ_ByGrp_3_SD: Standard deviation (SD)
            > Mth02_ContVar_Summ_ByGrp_4_Median: Median (Median)
            > Mth02_ContVar_Summ_ByGrp_5_Q1: First quartile (Q1)
            > Mth02_ContVar_Summ_ByGrp_6_Q3: Third quartile (Q3)
            > Mth02_ContVar_Summ_ByGrp_7_Min: Minimum (Min)
            > Mth02_ContVar_Summ_ByGrp_8_Max: Maximum (Max)
    1.2.2. Comparison by Treatment
      Analysis: An03.01_Age_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADSL.AGE
        Method: Analysis of variance group comparison for a continuous variable
          Operations:
            > Mth04_ContVar_Comp_Anova_1_pval: P-value (p-value)
  1.3. Age Group
    1.3.1. Summary of Subjects by Treatment
      Analysis: An03.02_AgeGrp_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Age Group [Results per group: Y]:
             1. < 65 years [ADSL.AGEGR1 EQ '<65']
             2. ≥ 65 years [ADSL.AGEGR1 IN ('65-80', '>80')]
        Analysis Variable: ADSL.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    1.3.2. Comparison of Subjects by Treatment
      Analysis: An03.02_AgeGrp_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Age Group [Results per group: N]:
             1. < 65 years [ADSL.AGEGR1 EQ '<65']
             2. ≥ 65 years [ADSL.AGEGR1 IN ('65-80', '>80')]
        Analysis Variable: ADSL.USUBJID
        Method: Pearson's chi-square test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_PChiSq_1_pval: P-value (p-value)
  1.4. Sex
    1.4.1. Summary of Subjects by Treatment
      Analysis: An03.03_Sex_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Gender [Results per group: Y]:
             1. Male [ADSL.SEX EQ 'M']
             2. Female [ADSL.SEX EQ 'F']
        Analysis Variable: ADSL.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    1.4.2. Comparison of Subjects by Treatment
      Analysis: An03.03_Sex_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Gender [Results per group: N]:
             1. Male [ADSL.SEX EQ 'M']
             2. Female [ADSL.SEX EQ 'F']
        Analysis Variable: ADSL.USUBJID
        Method: Pearson's chi-square test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_PChiSq_1_pval: P-value (p-value)
  1.5. Ethnicity
    1.5.1. Summary of Subjects by Treatment
      Analysis: An03.04_Ethnic_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Ethnicity [Results per group: Y]:
             1. Hispanic or Latino [ADSL.ETHNIC EQ 'HISPANIC OR LATINO']
             2. Not Hispanic or Latino [ADSL.ETHNIC EQ 'NOT HISPANIC OR LATINO']
        Analysis Variable: ADSL.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    1.5.2. Comparison of Subjects by Treatment
      Analysis: An03.04_Ethnic_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Ethnicity [Results per group: N]:
             1. Hispanic or Latino [ADSL.ETHNIC EQ 'HISPANIC OR LATINO']
             2. Not Hispanic or Latino [ADSL.ETHNIC EQ 'NOT HISPANIC OR LATINO']
        Analysis Variable: ADSL.USUBJID
        Method: Pearson's chi-square test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_PChiSq_1_pval: P-value (p-value)
  1.6. Race
    1.6.1. Summary of Subjects by Treatment
      Analysis: An03.05_Race_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Primary Race [Results per group: Y]:
             1. American Indian or Alaska Native [ADSL.RACE EQ 'AMERICAN INDIAN OR ALASKA NATIVE']
             2. Asian [ADSL.RACE EQ 'ASIAN']
             3. Black or African American [ADSL.RACE EQ 'BLACK OR AFRICAN AMERICAN']
             4. Native Hawaiian or Other Pacific Islander [ADSL.RACE EQ 'NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER']
             5. White [ADSL.RACE EQ 'WHITE']
             6. Multiple [ADSL.RACE EQ 'MULTIPLE']
             7. Not Reported [ADSL.RACE EQ 'NOT REPORTED']
             8. Unknown [ADSL.RACE EQ 'UNKNOWN']
             9. Other [ADSL.RACE EQ 'OTHER']
        Analysis Variable: ADSL.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    1.6.2. Comparison of Subjects by Treatment
      Analysis: An03.05_Race_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. Primary Race [Results per group: N]:
             1. American Indian or Alaska Native [ADSL.RACE EQ 'AMERICAN INDIAN OR ALASKA NATIVE']
             2. Asian [ADSL.RACE EQ 'ASIAN']
             3. Black or African American [ADSL.RACE EQ 'BLACK OR AFRICAN AMERICAN']
             4. Native Hawaiian or Other Pacific Islander [ADSL.RACE EQ 'NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER']
             5. White [ADSL.RACE EQ 'WHITE']
             6. Multiple [ADSL.RACE EQ 'MULTIPLE']
             7. Not Reported [ADSL.RACE EQ 'NOT REPORTED']
             8. Unknown [ADSL.RACE EQ 'UNKNOWN']
             9. Other [ADSL.RACE EQ 'OTHER']
        Analysis Variable: ADSL.USUBJID
        Method: Pearson's chi-square test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_PChiSq_1_pval: P-value (p-value)
  1.7. Height
    1.7.1. Summary by Treatment
      Analysis: An03.06_Height_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADSL.HEIGHTBL
        Method: Summary by group of a continuous variable
          Operations:
            > Mth02_ContVar_Summ_ByGrp_1_n: Count of non-missing values (n)
            > Mth02_ContVar_Summ_ByGrp_2_Mean: Mean (Mean)
            > Mth02_ContVar_Summ_ByGrp_3_SD: Standard deviation (SD)
            > Mth02_ContVar_Summ_ByGrp_4_Median: Median (Median)
            > Mth02_ContVar_Summ_ByGrp_5_Q1: First quartile (Q1)
            > Mth02_ContVar_Summ_ByGrp_6_Q3: Third quartile (Q3)
            > Mth02_ContVar_Summ_ByGrp_7_Min: Minimum (Min)
            > Mth02_ContVar_Summ_ByGrp_8_Max: Maximum (Max)
    1.7.2. Comparison by Treatment
      Analysis: An03.06_Height_Comp_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADSL.HEIGHTBL
        Method: Analysis of variance group comparison for a continuous variable
          Operations:
            > Mth04_ContVar_Comp_Anova_1_pval: P-value (p-value)
2. Overall Summary of Treatment-Emergent Adverse Events
  Output: Out14.3.1.1
  2.1. At Least One TEAE
    2.1.1. Summary of Subjects by Treatment
      Analysis: An07.01_TEAE_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events [ADAE.TRTEMFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADAE.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    2.1.2. Comparison of Subjects by Treatment - Placebo vs Low Dose
      Analysis: An07.01_TEAE_Comp_ByTrt_PlacLow
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and Low Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline Low Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
    2.1.3. Comparison of Subjects by Treatment - Placebo vs High Dose
      Analysis: An07.01_TEAE_Comp_ByTrt_PlacHigh
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and High Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline High Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
  2.2. Summary of Subjects with At Least One Related TEAE, by Treatment
    Analysis: An07.02_RelTEAE_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Related Treatment-Emergent Adverse Events [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AEREL IN ('POSSIBLE', 'PROBABLE'))]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.3. Summary of Subjects with At Least One Serious TEAE, by Treatment
    Analysis: An07.03_SerTEAE_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Serious Treatment-Emergent Adverse Events [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AESER EQ 'Y')]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.4. Summary of Subjects with At Least One Related Serious TEAE, by Treatment
    Analysis: An07.04_RelSerTEAE_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Related Serious Treatment-Emergent Adverse Events [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AEREL IN ('POSSIBLE', 'PROBABLE') AND ADAE.AESER EQ 'Y')]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.5. Summary of Subjects with At Least One TEAE Leading to Death, by Treatment
    Analysis: An07.05_TEAELd2Dth_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Treatment-Emergent Adverse Events Leading to Death [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AESDTH EQ 'Y')]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.6. Summary of Subjects with At Least One Related TEAE Leading to Death, by Treatment
    Analysis: An07.06_RelTEAELd2Dth_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Related Treatment-Emergent Adverse Events Leading to Death [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AESDTH EQ 'Y' AND (ADAE.AEREL EQ 'POSSIBLE' OR ADAE.AEREL EQ 'PROBABLE'))]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.7. Summary of Subjects with At Least One TEAE Leading to Dose Modification, by Treatment
    Analysis: An07.07_TEAELd2DoseMod_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Treatment-Emergent Adverse Events Leading to Dose Modification [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AEACN IN ('DOSE REDUCED', 'DRUG INTERRUPTED'))]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
  2.8. Summary of Subjects with At Least One TEAE Leading to Treatment Discontinuation, by Treatment
    Analysis: An07.08_TEAELd2TrtDsc_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Treatment-Emergent Adverse Events Leading to Treatment Discontinuation [(ADAE.TRTEMFL EQ 'Y' AND ADAE.AEACN EQ 'DRUG WITHDRAWN')]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
      Analysis Variable: ADAE.USUBJID
      Method: Summary by group of a categorical variable
        Operations:
          > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
          > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
            - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
            - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
3. Summary of TEAE by System Organ Class and Preferred Term
  Output: Out14.3.2.1
  3.1. System Organ Class
    3.1.1. Summary of Subjects by Treatment and System Organ Class
      Analysis: An07.09_Soc_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events [ADAE.TRTEMFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    3.1.2. Comparison of Subjects with TEAEs by Treatment and System Organ Class - Placebo vs Low Dose
      Analysis: An07.09_Soc_Comp_ByTrt_PlacLow
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and Low Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline Low Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
    3.1.3. Comparison of Subjects with TEAEs by Treatment and System Organ Class - Placebo vs High Dose
      Analysis: An07.09_Soc_Comp_ByTrt_PlacHigh
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and High Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline High Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
  3.2. Preferred Term
    3.2.1. Summary of Subjects by Treatment, System Organ Class and Preferred Term
      Analysis: An07.10_SocPt_Summ_ByTrt
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events [ADAE.TRTEMFL EQ 'Y']
        Groupings:
          1. Treatment [Results per group: Y]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
          3. Preferred Term [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Summary by group of a categorical variable
          Operations:
            > Mth01_CatVar_Summ_ByGrp_1_n: Count of subjects (n)
            > Mth01_CatVar_Summ_ByGrp_2_pct: Percent of subjects (%)
              - Numerator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for this analysis
              - Denominator: result of operation Mth01_CatVar_Summ_ByGrp_1_n for analysis An01.05_SAF_Summ_ByTrt
    3.2.2. Comparison of Subjects with TEAEs by Treatment, System Organ Class and Preferred Term - Placebo vs Low Dose
      Analysis: An07.10_SocPt_Comp_ByTrt_PlacLow
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and Low Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline Low Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
          3. Preferred Term [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
    3.2.3. Comparison of Subjects with TEAEs by Treatment, System Organ Class and Preferred Term - Placebo vs High Dose
      Analysis: An07.10_SocPt_Comp_ByTrt_PlacHigh
        Population: Safety Population [ADSL.SAFFL EQ 'Y']
        Data Subset: Treatment-Emergent Adverse Events for Placebo and High Active Dose [(ADAE.TRTEMFL EQ 'Y' AND ADSL.TRT01A IN ('Placebo', 'Xanomeline High Dose'))]
        Groupings:
          1. Treatment [Results per group: N]:
             1. Placebo [ADSL.TRT01A EQ 'Placebo']
             2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
             3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
          2. System Organ Class [Results per group: Y]: [Data-driven]
          3. Preferred Term [Results per group: Y]: [Data-driven]
        Analysis Variable: ADAE.USUBJID
        Method: Fisher's exact test group comparison for a categorical variable
          Operations:
            > Mth03_CatVar_Comp_FishEx_1_pval: P-value (p-value)
4. Summary of Observed and Change from Baseline by Scheduled Visits - Vital Signs
  Output: Out14.3.3.1a
  4.1. Summary of Observed Value by Treatment, Parameter and Visit
    Analysis: An08.01_Obs_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Vital Signs Analysis Records [ADVS.ANL01FL EQ 'Y']
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        2. Parameter [Results per group: Y]:
           1. Systolic Blood Pressure (mmHg) [ADVS.PARAMCD EQ 'SYSBP']
           2. Diastolic Blood Pressure (mmHg) [ADVS.PARAMCD EQ 'DIABP']
           3. Pulse Rate (beats/min) [ADVS.PARAMCD EQ 'PULSE']
           4. Temperature (C) [ADVS.PARAMCD EQ 'TEMP']
        3. Visit [Results per group: Y]:
           1. Baseline [ADVS.AVISIT EQ 'Baseline']
           2. Week 2 [ADVS.AVISIT EQ 'Week 2']
           3. Week 4 [ADVS.AVISIT EQ 'Week 4']
           4. Week 6 [ADVS.AVISIT EQ 'Week 6']
           5. Week 8 [ADVS.AVISIT EQ 'Week 8']
           6. Week 12 [ADVS.AVISIT EQ 'Week 12']
           7. Week 16 [ADVS.AVISIT EQ 'Week 16']
           8. Week 20 [ADVS.AVISIT EQ 'Week 20']
           9. Week 24 [ADVS.AVISIT EQ 'Week 24']
           10. Week 26 [ADVS.AVISIT EQ 'Week 26']
           11. End of Treatment [ADVS.AVISIT EQ 'End of Treatment']
      Analysis Variable: ADVS.AVAL
      Method: Summary by group of a continuous variable
        Operations:
          > Mth02_ContVar_Summ_ByGrp_1_n: Count of non-missing values (n)
          > Mth02_ContVar_Summ_ByGrp_2_Mean: Mean (Mean)
          > Mth02_ContVar_Summ_ByGrp_3_SD: Standard deviation (SD)
          > Mth02_ContVar_Summ_ByGrp_4_Median: Median (Median)
          > Mth02_ContVar_Summ_ByGrp_5_Q1: First quartile (Q1)
          > Mth02_ContVar_Summ_ByGrp_6_Q3: Third quartile (Q3)
          > Mth02_ContVar_Summ_ByGrp_7_Min: Minimum (Min)
          > Mth02_ContVar_Summ_ByGrp_8_Max: Maximum (Max)
  4.2. Summary of Change from Baseline by Treatment, Parameter and Visit
    Analysis: An08.02_ChgBl_Summ_ByTrt
      Population: Safety Population [ADSL.SAFFL EQ 'Y']
      Data Subset: Vital Signs Non-baseline Analysis Records [(ADVS.ANL01FL EQ 'Y' AND ADVS.AVISIT NE 'Baseline')]
      Groupings:
        1. Treatment [Results per group: Y]:
           1. Placebo [ADSL.TRT01A EQ 'Placebo']
           2. Xanomeline Low Dose [ADSL.TRT01A EQ 'Xanomeline Low Dose']
           3. Xanomeline High Dose [ADSL.TRT01A EQ 'Xanomeline High Dose']
        2. Parameter [Results per group: Y]:
           1. Systolic Blood Pressure (mmHg) [ADVS.PARAMCD EQ 'SYSBP']
           2. Diastolic Blood Pressure (mmHg) [ADVS.PARAMCD EQ 'DIABP']
           3. Pulse Rate (beats/min) [ADVS.PARAMCD EQ 'PULSE']
           4. Temperature (C) [ADVS.PARAMCD EQ 'TEMP']
        3. Visit [Results per group: Y]:
           1. Baseline [ADVS.AVISIT EQ 'Baseline']
           2. Week 2 [ADVS.AVISIT EQ 'Week 2']
           3. Week 4 [ADVS.AVISIT EQ 'Week 4']
           4. Week 6 [ADVS.AVISIT EQ 'Week 6']
           5. Week 8 [ADVS.AVISIT EQ 'Week 8']
           6. Week 12 [ADVS.AVISIT EQ 'Week 12']
           7. Week 16 [ADVS.AVISIT EQ 'Week 16']
           8. Week 20 [ADVS.AVISIT EQ 'Week 20']
           9. Week 24 [ADVS.AVISIT EQ 'Week 24']
           10. Week 26 [ADVS.AVISIT EQ 'Week 26']
           11. End of Treatment [ADVS.AVISIT EQ 'End of Treatment']
      Analysis Variable: ADVS.CHG
      Method: Summary by group of a continuous variable
        Operations:
          > Mth02_ContVar_Summ_ByGrp_1_n: Count of non-missing values (n)
          > Mth02_ContVar_Summ_ByGrp_2_Mean: Mean (Mean)
          > Mth02_ContVar_Summ_ByGrp_3_SD: Standard deviation (SD)
          > Mth02_ContVar_Summ_ByGrp_4_Median: Median (Median)
          > Mth02_ContVar_Summ_ByGrp_5_Q1: First quartile (Q1)
          > Mth02_ContVar_Summ_ByGrp_6_Q3: Third quartile (Q3)
          > Mth02_ContVar_Summ_ByGrp_7_Min: Minimum (Min)
          > Mth02_ContVar_Summ_ByGrp_8_Max: Maximum (Max)
